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ABSTRACT 
Community-acquired respiratory tract infections are one of the commonest infections seen in the clinical practice and an 
important cause of mortality and morbidity, especially in patients with immune-compromised states. Two cases of antibiotic 
resistant community-acquired lower respiratory tract infections in a 42-year-old male and a 68-year-old male are reported. 
Both had presented with lower respiratory tract symptoms, previously treated with antibiotics. The patients were immune-
compromised and suffered from conditions such as Diabetes and COPD. Along with this, they had an infection caused by 
resistant bacteria. The clinical history, investigations and the appropriate line of treatment selected in order to resolve 
complications in the present cases are detailed here. 
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oday, antibiotic resistance has become a serious 
public health problem with economic and social 
implications, including higher rates of 
hospitalization, longer hospital stay and increase in the 
cost of treatment. In our country, the bacterial disease 
burden is the highest, with infections such as pneumonia 
leading to 410,000 deaths annually [1]. In both inpatients 
and outpatients, the most common pathogens associated 
with community-acquired pneumonia (CAP) include 
Streptococcus pneumoniae, Haemophilus influenzae; 
group A streptococci and Moraxella catarrhalis [2]. They 
are known to produce different types of beta-lactamases 
that confer drug resistance. 
A collaborative study from eight Asian countries, 
including India, has revealed that 35.1% of the total 
resistance is to S. pneumoniae [3].  There are similar other 
reports showing multidrug resistance to H. influenzae, 
ranging from 24 to 36.6%; for M. catarrhalis, it is at 86.2 
to 96.8%. [4]. Increase in the rates of resistance has 
contributed to an increase in patient mortality. Many of 
these deaths also occur because the patients cannot afford 
the cost of healthcare facilities and do not have access to 
life saving medicines when they are needed most [5]. The 
two cases presented here are examples of situations in 
which the patient doesn’t want to get hospitalized because 
of his economic status but is suffering from multiple 
disorders along with infection that was caused by a 
resistant bacterium.  
CASE REPORTS 
Case 1 
A 42-year-old male had presented with complaints of 
cough with yellowish expectoration of sputum for the past 
one week along with high grade intermittent fever. Patient 
belonged to a middle class working family. There was 
T 
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history of diabetes mellitus (type II) for the past 4 years 
and for which he was taking on oral hypoglycemic drugs 
(glimiperide and metformin). He was a regular smoker 
with a family h/o coronary artery disease). There was also 
a history of allergy to macrolides. He was treated by a 
local physician with oral levofloxacin (500mg/day for 5 
days) without much relief. So, he approached to a 
pulmonary physician who advised a chest X-ray and 
sputum examination.  
On examination, his vitals were within normal limits 
(pulse rate - 95/min, blood pressure - 132/86 mmHg and 
respiratory rate - 25/min, SpO2 – 90% on room air). There 
was no pallor, icterus, clubbing, edema or 
lymphadenopathy. Respiratory system examination 
showed rales in right mammary and axillary areas. Rest of 
systemic examination revealed no significant abnormality. 
His fasting blood sugar was 121 mg% and post-prandial 
sugar was 179 mg%, HbA1c was 8.1%. His total leukocyte 
counts were 12,300 cells/mm
3
 (82% were polymorphs) and 
normal platelet counts. Chest X-ray was suggestive of 
right upper lobe pneumonia (Fig 1).  
 
Figure 1 - Chest X-ray suggestive of Right Upper Lobe 
Pneumonia 
The sputum had a heavy growth of Streptococcus, 
which was resistant to most antibiotics, including 
amoxicillin, levofloxacin, ciprofloxacin, ofloxacin and 
cephalexin. It was susceptible only to carbapenems and 
third-generation cephalosporins. As patient was not ready 
for admission so he was started with oral penem 
(Faropenem 200 mg thrice a day) along with cough 
expectorants and bronchodilators. His symptoms improved 
after 5 days of therapy with decreased intensity of cough 
and fever both. 
Case 2  
A 68-year-old male with moderate chronic obstructive 
pulmonary disease (COPD) presented with increased 
sputum volume and purulence for the past 6 days 
associated with more shortness of breath (mMRC Grade 
II). He also complained of lethargy and feverishness. He 
was a hypertensive and diabetic, being on oral 
hypoglycemic agents (OHAs) for the past 2 years. He had 
a smoking history of 20 pack-years, which he had quit on 
the physician’s advice 5 years back. He had a history of 
contact with pulmonary tuberculosis in the household; 
though, he had no history of taking anti-tubercular drugs 
for himself. The patient had three exacerbations of 
shortness of breath in the past 2 months, which was treated 
with oral antibiotics comprising of co-amoxyclav, 
cefuroxime and gemifloxacin.  
On examination, he was afebrile with heart rate of 
78/min and respiratory rate of 28/min; however, SPO2 at 
room air was 92%. Blood pressure was 160/90 mmHg, 
there was no dependent edema. Examination of the 
respiratory system revealed prolonged expiration with 
polyphonic rhonchi. A clinical diagnosis of acute 
exacerbations of COPD (AE-COPD) was made. Rest of 
the systemic examination was normal.  
 
Figure 2 - Chest X-ray showing a hyper lucent lung 
fields  
On laboratory investigations, his total leukocyte count 
was 10,000/mm
3
 with neutrophilia (80% neutrophils), and 
elevated CRP levels (70 mg/l) and serum creatinine was 
1.02 mg%. Sputum examination by Gram’s staining and 
culture was non-contributory and it grew only commensal 
organisms. Chest X-ray showed no evidence of 
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consolidation, but showed a hyperlucent lung (Fig 2). His 
fasting blood sugar was 130 mg/dl and random blood 
sugar was 168 mg/dl with HbA1c of 7.5%. Arterial Blood 
Gas analysis showed pH - 7.36, PaO2 - 70 mmHg, and 
PaCO2 - 50 mmHg at room air.  
Taking into account the history of three exacerbations 
in past two months with worsening of symptoms; the 
patient was put on inhaled bronchodilators with regular 
inhaled corticosteroids. The inhalation technique was 
rechecked. Oral corticosteroids were started at 1 mg/kg 
body weight for 2 weeks along with a broad spectrum 
antibiotic which was not prescribed earlier. He was 
prescribed faropenem 200 mg thrice daily for 7 days. 
Good diabetic control along with a diet, OHAs and anti-
hypertensives was suggested. A revisit was scheduled after 
7 days and the patient was found to be much better, with 
stable vitals and diminished breathlessness. 
DISCUSSION 
Antibiotic resistance has become a serious public health 
concern with economic and social implication throughout 
the world. Drugs used clinically in the empirical treatment 
of community-acquired respiratory tract infections 
currently include beta-lactams, macrolides and respiratory 
quinolones [6]. But, growing resistance rates to these 
antibiotics had reduced the therapeutic options for the 
treatment of intractable infections. [7]  
These two cases demonstrated the management of 
patients with CAP and AE-COPD with various co-
morbidities. In case 1, the patient’s pre-existing conditions 
or “co-morbidities” such as diabetes (HbA1C - 8.1%) and 
chronic smoking aggravated his condition and increase the 
risk of serious infections [8]. The patient’s sputum had 
grown “Streptococcus”, resistant to most of the drugs 
(fluroquinolones and beta-lactams). In view of the co-
morbids and drug resistance of the organism, treatment 
was started with oral faropenem for 1 week as he did not 
want to get hospitalized. By end of the second day, he was 
symptomatically better and by end of the fifth day, he was 
completely asymptomatic.  
The clinical efficacy of faropenem is previously 
studied in certain trials on upper and lower respiratory 
tract infections, which attest its potential. Though, the 
trials are limited; current usage is based on in vitro 
assessments and clinical expertise. Currently faropenem is 
registered for use only in Japan and India, it is not US 
FDA approved [9] [10]. 
In case 2, culture report was indecisive; however, 
patient was apprised of severity and was advised 
hospitalization but he declined hospitalization and opted 
for home care. Taking into account the history of three 
exacerbations in past two months with worsening of 
symptoms, patient was put on broad spectrum oral 
antibiotic faropenem. It’s a recognized fact that evaluation 
of bacterial infection in exacerbation is challenging, as 
airways of COPD patients are usually colonized by H. 
influenzae, S.pneumoniae, and M. catarrhalis. However, 
bacteria are the primary cause of exacerbation; and they 
may also act as a secondary invader after acute viral or 
mycoplasma infections, hence the therapeutic options for 
management of AE-COPD includes antibiotics along with 
corticosteroids, inhaled bronchodilators and oxygen 
therapy [6, 11].  
Patients with co-morbidities are at increased risk of 
respiratory tract infections. Such cases are routinely 
treated either with a fluroquinolones or beta lactam plus 
macrolides, but the increasing resistance trends have made 
the choice of antibiotic difficult over the period of time. 
The antimicrobial class of penems are said to have the 
potential to address most of the relevant resistance issues 
associated with beta-lactam antibiotics. They have a very 
good intrinsic stability against hydrolytic attack by many 
beta-lactamases, including ESBL and AmpC enzymes [12, 
13].  
Being a new molecule, faropenem could help in 
tackling the resistance issue at present, but it should be 
cautiously used, considering the severity parameters. This 
molecule has a good in-vitro and in-vivo efficacy as 
reported in few articles, but more randomized trials are 
warranted in the Indian populations. 
CONCLUSION 
Current cases are the examples of infections caused by 
resistant bacteria in patients with various co-morbidities, 
where the first line of treatment with antibiotics had failed 
and patients were prescribed an oral penem. However, it 
should be strictly reserved as a second line treatment only 
for resistant cases based on the susceptibility outcomes.  
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